|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recombinant, activated factor VH forsurgery in factor VH deficiency : aprospective evaluation - the surgical STER显示文摘 | Mariani G Dolce A Batorova A | 2010 | British Journal of Haematology2010，152，3： | 1 |
| 2 | Continuous infusion of coagulation factors : current opinion显示文摘 | Batorova A Martinowitz U | 2006 | Curr Opin Hematol2006，13，5： | 1 |
| 3 | Replacement therapy for invasive procedures in patients with haemophilia:literature review,European survey and recommendations显示文摘 | Hermans C Altisent C Batorova A | 2009 | Haemophilia2009，15，3： | 1 |
| 4 | Changing insights in the diagnosis and classification of autosomal recessive and dominant von Willebrand diseases 1980-2015显示文摘The European Clinical Laboratory and Molecular(ECLM) criteria define 10 distinct Willebrand diseases(VWD) recessive type 3, severe 1, 2C and 2N; dominant VWD type 1 secretion/clearance defect, 2A, 2B, 2E, 2M and 2D; and mild type 1 VWD(usually carriers of recessive VWD). Recessive severe 1 and 2C VWD are characterized by secretion and multimerization defects caused by mutations in the D1-D2 domain. Recessive 2N VWD is a mild hemophilia due to D'-FVIII-von Willebrand factor(VWF) binding site mutations. Dominant 2E VWD caused by heterozygous missense mutations in the D3 domain is featured by a secretion-clearancemultimerization VWF defect. Dominant VWD type 2M due to loss of function mutations in the A1 domain is characterized by decreased ristocetin-induced platelet aggregation and VWF RCo, normal VWF multimers and VWF CB, a poor response of VWF RCo and good response of VWF CB to desmopressin(DDAVP). Dominant VWD type 2A induced by heterozygous mutations in the A2 domain results in hypersensitivity of VWF for proteolysis by ADAMTS13 into VWF degradationproducts, resulting in loss of large VWF multimers with triplet structure of each individual VWF band. Dominant VWD type 2B due to a gain of function mutation in the A1 domain is featured by spontaneous interaction between platelet glycoprotein Ib(GPIb) and mutated VWF A1 followed by increased proteolysis with loss of large VWF multimers and presence of each VWF band. A new category of dominant VWD type 1 secretion or clearance defect due to mutations in the D3 domain or D4-C1-C5 domains consists of two groups Those with normal or smeary pattern of VWF multimers. | Jan Jacques Michiels Angelika Batorova Tatiana Prigancova Petr Smejkal Miroslav Penka Inge Vangenechten Alain Gadisseur | 2016 | World Journal of Hematology2016，5，3： | 1 |
| 5 | Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion显示文摘 | Vu D de Moerloose P Batorova A | 2005 | J Med Genet2005，42，9： | 1 |
| 6 | Comprehensive care for haemophilia around the world 显示文摘 | Evatt BL Black C Batorova A | 2004 | Haemophilia2004，，4： | 1 |
| 7 | Non-genetic risk factorsand the development of inhibitors in haemophilia:a comprehensivereview and consensus report显示文摘 | Astermark J Altisent C Batorova A | 2010 | Haemophilia2010，16，5： | 1 |
| 8 | Rare bleeding disorders显示文摘 | Peyvandi F Bolton-Maqqs PH Batorova A | 2012 | Haemophilia2012，184，： | 1 |
| 9 | Replacement therapy for invasive procedures in patients with haemophilia:literature review,European survey and recommendations显示文摘 | Hermans C Altisent C Batorova A | 2009 | Haemophilia2009，15，3： | 1 |
| 10 | Clinical efficacy of a novel VWF-containing FVIII eoncentrate,Wilate(?),in the prophylaxis and treatment of bleeding episodes in previously treated haemo philia A patients显示文摘 | Klukowska A Windyga J Batorova A | 2011 | Thromb Res2011，127，3： | 1 |
| 11 | Comprehensivecare for haemophilia around the world 显示文摘 | EVATT B BLACK C BATOROVA A | 2004 | Haemophilia2004，10，4： | 1 |
| 12 | Replacement therapy for nvasive proce-dures in patients with haemophilia: literature review, European survey and recommendations 显示文摘 | Hermans C Altisent C Batorova A | 2009 | Haemophilia2009，15，3： | 1 |
| 13 | Continuous infusion of coagulation factors:current opinion显示文摘 | Batorova A Martinowitz U | 2006 | Curr Opin Hematol2006，13，5： | 1 |
| 14 | Continuous infusion of coagulation factors: current opinion显示文摘 | Batorova A Martinowitz U | 2006 | Curr Opin Hematol2006，13，5： | 1 |
| 15 | Non genetic risk factors and the development of inhibitors in haemophilia:a comprehensive review and consensus report显示文摘 | Astermark J Altisent C Batorova A | | 0，，05： | 1 |
| 16 | Rare bleeding disorder显示文摘 | PEYVANDI F BOLTON-MAGGS PH BATOROVA A | | 0，，4： | 1 |
| 17 | Recombinant,activated factor Ⅶ for surgery in factor Ⅶ deficiency:a prospective evaluation-the surgical STER显示文摘 | MARIANI G DOLCE A BATOROVA A | | 0，，03： | 1 |
| 18 | Comprehensive care for haemophi lia around the world显示文摘 | Evatt BL Black C Batorova A | 2004 | Haemophilia2004，10，4： | 1 |
| 19 | Continuous infusion of coagu- lation factors: current opinion 显示文摘 | Batorova A Martinowitz U | 2006 | Curr Opin Hematol2006，13，5： | 1 |
| 20 | Continuous infusion of coagulation factors:current opinion显示文摘 | Batorova A Martinowitz U | 2006 | Curr Opin Hematol2006，13，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员